Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Health / Medical

Virpax Pharmaceuticals
Research

Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results

February 16, 2025February 15, 2025 - by Timothy Alexander

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced the successful completion of a full study on its localized pain management product, Probudur™, conducted in partnership with the U.S. Army …

Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results Read More

PleoPharma
Research

FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome

February 15, 2025February 14, 2025 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis …

FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome Read More
Ocugen
Research

Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!

February 13, 2025February 12, 2025 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …

Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More

Aclaris Therapeutics
Research

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor

February 12, 2025February 12, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK …

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor Read More
MAXONA Pharmaceuticals
Research

MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy

February 12, 2025February 11, 2025 - by Timothy Alexander

MALVERN, PA — MAXONA Pharmaceuticals has officially emerged from stealth mode, announcing the successful completion of its U.S. Phase 1 clinical trials for MAX-001, a groundbreaking non-opioid, non-NSAID oral therapy designed …

MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy Read More

Palvella Therapeutics
Research

Palvella Therapeutics Expands Phase 3 Trial to Younger Patients

February 11, 2025February 10, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), to include children as young …

Palvella Therapeutics Expands Phase 3 Trial to Younger Patients Read More
Silver Lining Clinics by MoodRx LLC
Mental Health / Senior Citizens

Silver Lining Clinics Launches Medicare-Covered Therapy for Seniors

February 11, 2025February 10, 2025 - by Timothy Alexander

WAYNE, PA — Silver Lining Clinics LLC, a subsidiary of MoodRx LLC, is set to launch its revolutionary mental health service for seniors on February 14, 2025. Designed to address critical …

Silver Lining Clinics Launches Medicare-Covered Therapy for Seniors Read More

Smartphone in park
Diabetes / National

Stay Alert: FDA Warns Diabetes Patients About Smartphone Device Risks

February 10, 2025February 9, 2025 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has issued a safety communication warning users of smartphone-compatible diabetes devices about potential risks stemming from missed or undelivered alerts. …

Stay Alert: FDA Warns Diabetes Patients About Smartphone Device Risks Read More
The Wistar Institute
Cancer / Regional

Wistar Institute Uncovers New Strategy for Treating Resistant Melanoma

February 7, 2025February 6, 2025 - by Timothy Alexander

PHILADELPHIA, PA— Researchers at The Wistar Institute, led by Jessie Villanueva, Ph.D., have made significant strides in combating treatment-resistant melanoma. Their latest discovery focuses on inhibiting the gene S6K2, a breakthrough …

Wistar Institute Uncovers New Strategy for Treating Resistant Melanoma Read More
Annovis Bio
Research

Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap

February 6, 2025February 5, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …

Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More

Posts pagination

Previous 1 … 43 44 45 … 52 Next

Trending News

  • South Coventry Township: Where Iron, Forest, and Village Life Endure

  • Demonstrating Failsafe Communications in a Disaster

  • Man Wounded in Wilmington Shooting as Police Seek Answers

  • Survey Links CMS Payment Rule to Wound Care Access Strains

  • Men’s Health Month Has a Message Many Men Need to Hear

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Crime scene do not cross signage

Man Wounded in Wilmington Shooting as Police Seek Answers

5 hours ago8 hours ago

Foreclosure

VA Launches Foreclosure Relief Program for At-Risk Veterans

June 21, 2026June 20, 2026

Thomas Coleman

Daycare Employee Charged After Child Assault Allegation

June 20, 2026June 20, 2026

Copyright © 2026 MyChesCo.